Tariq Mahmood Khan, Sohail Iqbal, Muhammad Adnan Rashid


Background: Extra virgin olive oil (EVOO) is fruit oil with rich source of monounsaturated fats and powerful antioxidants. It acts as hypolipidemic agent and significant decrease of plasma lipids levelwas observed with EVOO use. Atorvastatin is hypolipidemic drug commonly used for treatment of hyperlipidaemia. The purpose of this study was to determine & compare the lipid lowering effect of EVOO with atorvastatin in type 2 diabetic dyslipidaemia which is leading cause of microvascular diseases. Methods: This cross-sectional study was conducted on 60 already diagnosed cases of type 2 diabetes mellitus with dyslipidaemia. All sixty subjects were divided into 2 groups. Atorvastatin 40mg was given to Group One and two tablespoons of extra virgin olive oil orally per day was given to Group Two. Blood was collected for estimation of plasma lipids level at base line, 4th week, and 6th weeks in two groups and was compared statistically. Results: The present study demonstrated 20–40% lipid lowering effect of atorvastatin on plasma lipids level with 9–16% increase in HDL while extra virgin olive oil showed 14 to 25% reduction in plasma lipids with 8–12% increase in HDL-cholesterol level.  Conclusion: This study concludes that both atorvastatin and extra virgin olive oil are effective in reducing plasma lipids level in type 2 diabetic dyslipidaemia with more prominent effect of atorvastatin than EVOO.

Keywords: Extra virgin olive oil (EVOO); Atorvastatin; Diabetic dyslipidaemia

Full Text:



Frier BM, Fisher M. Davidson principle and practice of medicine. Read Elsevier 2014. p.799–802.

Haffner SM, American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S83–6.

Mashrani U. Current medical diagnosis and treatment. Diabetes mellitus and hypoglycemia. McGraw Hill 2010. p-1079–88.

Tripathi K. Hypolipidemic Drug and Plasma Expanders. Essent Med Pharmacol 2004;5:557.

Richard F, Clark MA, Luigix C. Hyperlipidemia. Lippincott's illustrated review: Pharmacology. Lippincott Williams and Wilkins; 2009.

Bellosta S, Paoletti R, Corsini A. Atherosclerosis: Evolving vascular biology and clinical implications. Circulation 2004;109:50–7.

Kok FJ, Kromhout D. Atherosclerosis-epidemiological studies on the health effects of a Mediterranean diet. Eur J Nutr 2004;43(Suppl 1):2–5.

Sara G, Alessandra B, Elisa G. Cherry leaf roll virus: Impact on olive fruit and virgin olive oil quality. Eur J Lipid Sci Technol 2012;114(5):535–41.

Baggio G, Pagnan A, Muraca M, Martini S, Opportuno A, Bonanome A, et al. Olive-oil enriched diet: effect on serum lipoprotein levels and biliary cholesterol saturation. Am J Clin Nutr 1988;47(6):960–4.

Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, et al. The effect of plyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006;145(5):333–41.

Collins R, Peto R, Armtage J. The MRC/BHF Heart protection Study: preliminary results. Int J Clin Pract 2002;56(1):83–6.

Abbasi MA, Hafeezullah, Shah NA, Abro A, Sammo JA. Non high density lipoprotein cholesterol in type 2 diabetes mellitus. Pak J Physiol 2007;3(2):38–41.

Ravnskov U, Rosch P, Sutter MC, Houston MC. Should we lower cholesterol as much as possible? BMJ 2006;332(7553):1330–2.

Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000;75(9):933–42.

de Castro ML, Hermo JA, Baz A, de Luaces C, Pérez R, Clofent J. [Acute Cholestatic hepatitis after atorvastatin reintroduction]. Gastroenterol Hepatol 2006;29(1):21–4.

Cicero AF, Nascetti S, López-Sabater MC, Elosua R, Salonen JT, Nyyssönen K, et al. Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related to lipid oxidative damage: The EUROLIVE Study. J Am Clin Nutr 2008;27(2):314–20.

Covas MI. Olive oil and the cardiovascular system. Pharmacol Res 2007;55(3):175–86.

Haban P, Klvanova J, Zidekova E, Nagyova A. Dietary supplementation with olive oil leads to improved lipoprotein spectrum and lower n-6 PUFAs in elderly subjects. Med Sci Monit 2004;10(4):149–54.


  • There are currently no refbacks.

Contact Number: +92-992-382571

email: [jamc] [@] []